The beat is driven by cost cuts and a new revenue line, not pipeline progress. Watch for Phase 1 data readouts on PRT13722 and PRT12396 as the next catalysts; the cash runway into 2028 provides a long development horizon.
Price Chart
Executive Summary
Prelude Therapeutics reported Q2 2026 EPS of -$0.14, beating consensus of -$0.18 by 22.2%, and generated $5.7M in revenue (vs $0 consensus). Net loss narrowed to $13.9M from $31.2M a year ago, with cash runway into Q2 2028. The beat is driven by cost controls and a new revenue stream, but the company remains pre-revenue on its pipeline, limiting the stock-moving impact.
Key Financial Metrics
Key Facts
- Q2 2026 EPS -$0.14 beat consensus -$0.18 (22.2% beat)
- Revenue of $5.7M vs $0 consensus and $0 year-ago
- Net loss narrowed to $13.9M from $31.2M YoY
- Cash, equivalents, restricted cash, and marketable securities $155.2M as of June 30, 2026
- Cash runway expected into Q2 2028
- R&D expenses fell to $16.1M from $25.8M YoY; G&A fell to $5.0M from $6.4M
- Phase 1 study of PRT13722 (KAT6A degrader) expected to initiate in Q4 2026
- Enrollment continues in Phase 1 of PRT12396 (JAK2V617F inhibitor) for PV and MF
Financial Impact
EPS beat of $0.04 vs consensus; revenue surprise of $5.7M; net loss improvement of $17.3M YoY
Risk Factors
- Pre-revenue pipeline with no approved products; clinical trial risks for PRT13722 and PRT12396
- Revenue of $5.7M may be one-time or non-recurring; sustainability unclear
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342538 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $4.85 $4.31 | ▼ −11.13% | ▼ −10.41% | $3.69 (−23.81%) |
Sep 10, 2026 6w ago | 8-K | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.69 (−20.88%) |
Sep 10, 2026 6w ago | Press Release | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.69 (−20.88%) |
Aug 11, 2026 11w ago | 8-K | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.69 (−30.55%) |
Aug 11, 2026 11w ago | Press Release | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.69 (−30.55%) |
May 12, 2026 24w ago | 8-K | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.69 (−20.37%) |
May 12, 2026 24w ago | Press Release | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.69 (−20.37%) |
Apr 28, 2026 25w ago | 3 | $4.27 $4.27 | · 0.00% | ▼ −1.02% | $3.69 (−13.47%) |
Apr 21, 2026 27w ago | Insider Cluster | $4.27 $5.23 | ▲ +22.48% | ▲ +21.46% | $3.69 (−13.47%) |
Apr 20, 2026 27w ago | 8-K | $4.51 $4.62 | ▲ +2.44% | ▲ +3.09% | $3.69 (−18.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers